Drug Profile


Alternative Names: Olinvo; TRV-130; TRV130A

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Trevena
  • Class Analgesics; Small molecules
  • Mechanism of Action Beta arrestin inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Postoperative pain
  • Phase II Pain

Most Recent Events

  • 21 Feb 2017 Safety and efficacy data from the phase III APOLLO-1 and APOLLO-2 in Postoperative pain released by Trevena
  • 20 Feb 2017 Trevana completes the APOLLO-1 trial in Postoperative pain in USA (NCT02815709)
  • 04 Jan 2017 Trevena completes enrolment in the APOLLO-1 and APOLLO-2 phase III trials for Postoperative pain in USA (NCT02815709) (NCT02820324)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top